Patent intelligence · US
US 6436966
Adenosine A3 receptor antagonists
Adenosine A3 receptor antagonists
Patent details — US 6436966
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 20, 2002
- Expiration
- Aug 15, 2022
- Applicant
- Takeda Chemical Ind., Ltd.
- Claims
- 9
- CPC classes
- A61K, A61K31/4436, A61K31/4439, A61P
Quick answer
US 6436966 (Adenosine A3 receptor antagonists) is held by Takeda Chemical Ind., Ltd.. Status: expired. Granted Aug 20, 2002. Expires Aug 15, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Chemical Ind., Ltd.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/4436, A61K31/4439, A61P, A61P11/00, A61P11/06
More from Takeda Chemical Ind., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 6436966?
US 6436966 (Adenosine A3 receptor antagonists) is held by Takeda Chemical Ind., Ltd.. Status: expired. Granted Aug 20, 2002. Expires Aug 15, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6436966?
Takeda Chemical Ind., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 6436966 expire?
Our index shows an expiration date of Aug 15, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.